MAP2K7 and venous thromboembolism: Classification: RAF/MEK heterodimer breaker. Binds to the RAF/MEK interface. Prevents RAF/MEK association and MEK phosphorylation. PFS: 4.8 months (single agent), 11.0 months (combined with dabrafenib) ORR: 22% (single agent), 68% (combined with dabrafenib). OS (median): 15.6 months (single agent), 25.1 months (combined with dabrafenib). Side effects: hemorrhage, colitis, and venous thromboembolism. Clinically available (FDA approved in 2013 for single agent, also approved for combination therapy with dabrafenib in 2018)